Falkai, Peter Gaston

[["dc.bibliographiccitation.firstpage","142"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","170"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Lieberman, Jeffrey"],["dc.contributor.author","Glenthoj, Birte"],["dc.contributor.author","Gattaz, Wagner F."],["dc.contributor.author","Thibaut, Florence"],["dc.contributor.author","Moeller, Hans-Juergen"],["dc.date.accessioned","2018-11-07T09:59:10Z"],["dc.date.available","2018-11-07T09:59:10Z"],["dc.date.issued","2015"],["dc.description.abstract","These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia."],["dc.identifier.doi","10.3109/15622975.2015.1009163"],["dc.identifier.isi","352078300002"],["dc.identifier.pmid","25822804"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37530"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","1814-1412"],["dc.relation.issn","1562-2975"],["dc.title","World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","397"],["dc.bibliographiccitation.journal","Schizophrenia Research"],["dc.bibliographiccitation.lastpage","407"],["dc.bibliographiccitation.volume","216"],["dc.contributor.author","Takahashi, Shun"],["dc.contributor.author","Keeser, Daniel"],["dc.contributor.author","Rauchmann, Boris-Stephan"],["dc.contributor.author","Schneider-Axmann, Thomas"],["dc.contributor.author","Keller-Varady, Katriona"],["dc.contributor.author","Maurus, Isabel"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Ertl-Wagner, Birgit"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Falkai, Peter"],["dc.date.accessioned","2021-04-14T08:27:38Z"],["dc.date.available","2021-04-14T08:27:38Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.schres.2019.11.004"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82355"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0920-9964"],["dc.title","Effect of aerobic exercise combined with cognitive remediation on cortical thickness and prediction of social adaptation in patients with schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","26"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.lastpage","33"],["dc.bibliographiccitation.volume","91"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Lehmann, Isabel"],["dc.contributor.author","Janssen, Birgit"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Zielasek, Jürgen"],["dc.contributor.author","Gaebel, Wolfgang"],["dc.date.accessioned","2020-12-10T14:08:38Z"],["dc.date.available","2020-12-10T14:08:38Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s00115-019-00813-y"],["dc.identifier.eissn","1433-0407"],["dc.identifier.issn","0028-2804"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70501"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Die aktualisierte S3-Leitlinie Schizophrenie"],["dc.title.alternative","Revised S3 guidelines on schizophrenia. Developmental process and selected recommendations"],["dc.title.subtitle","Entwicklungsprozess und ausgewählte Empfehlungen"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","127"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","136"],["dc.bibliographiccitation.volume","265"],["dc.contributor.author","Kittel-Schneider, Sarah"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Scherk, Harald"],["dc.contributor.author","Schneider-Axmann, Thomas"],["dc.contributor.author","Trost, Sarah"],["dc.contributor.author","Zilles, David"],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Schmitt, A."],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Backens, Martin"],["dc.contributor.author","Reith, W."],["dc.contributor.author","Falkai, Peter Gaston"],["dc.contributor.author","Gruber, Oliver"],["dc.contributor.author","Reif, A."],["dc.date.accessioned","2018-11-07T10:00:31Z"],["dc.date.available","2018-11-07T10:00:31Z"],["dc.date.issued","2015"],["dc.description.abstract","The diacylglycerol kinase eta (DGKH) gene, first identified in a genome-wide association study, is one of the few replicated risk genes of bipolar affective disorder (BD). Following initial positive studies, it not only was found to be associated with BD but also implicated in the etiology of other psychiatric disorders featuring affective symptoms, rendering DGKH a cross-disorder risk gene. However, the (patho-)physiological role of the encoded enzyme is still elusive. In the present study, we investigated primarily the influence of a risk haplotype on amygdala volume in patients suffering from schizophrenia or BD as well as healthy controls and four single nucleotide polymorphisms conveying risk. There was a significant association of the DGKH risk haplotype with increased amygdala volume in BD, but not in schizophrenia or healthy controls. These findings add to the notion of a role of DGKH in the pathogenesis of BD."],["dc.description.sponsorship","DFG [RTG 1253/1, RE1632/5-1]; BMBF (DZHI) [01EO1004]; IZKF [Z3-24]"],["dc.identifier.doi","10.1007/s00406-014-0513-9"],["dc.identifier.isi","000350305500005"],["dc.identifier.pmid","24958494"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37825"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1433-8491"],["dc.relation.issn","0940-1334"],["dc.title","Influence of DGKH variants on amygdala volume in patients with bipolar affective disorder and schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","589"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","600"],["dc.bibliographiccitation.volume","265"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Wolff-Menzler, Claus"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Weidinger, Elif"],["dc.contributor.author","Jobst, Andrea"],["dc.contributor.author","Hoell, Imke"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Yeganeh-Doost, Peyman"],["dc.contributor.author","Strube, Wolfgang"],["dc.contributor.author","Quast, Silke"],["dc.contributor.author","Mueller, Norbert"],["dc.contributor.author","Wobrock, Thomas"],["dc.date.accessioned","2018-11-07T09:51:15Z"],["dc.date.available","2018-11-07T09:51:15Z"],["dc.date.issued","2015"],["dc.description.abstract","Despite many pharmacological and psychosocial treatment options, schizophrenia remains a debilitating disorder. Thus, new treatment strategies rooted in the pathophysiology of the disorder are needed. Recently, vagus nerve stimulation (VNS) has been proposed as a potential treatment option for various neuropsychiatric disorders including schizophrenia. The objective of this study was to investigate for the first time the feasibility, safety and efficacy of transcutaneous VNS in stable schizophrenia. A bicentric randomized, sham-controlled, double-blind trial was conducted from 2010 to 2012. Twenty schizophrenia patients were randomly assigned to one of two treatment groups. The first group (active tVNS) received daily active stimulation of the left auricle for 26 weeks. The second group (sham tVNS) received daily sham stimulation for 12 weeks followed by 14 weeks of active stimulation. Primary outcome was defined as change in the Positive and Negative Symptom Scale total score between baseline and week 12. Various other secondary measures were assessed to investigate safety and efficacy. The intervention was well tolerated with no relevant adverse effects. We could not observe a statistically significant difference in the improvement of schizophrenia psychopathology during the observation period. Neither psychopathological and neurocognitive measures nor safety measures showed significant differences between study groups. Application of tVNS was well tolerated, but did not improve schizophrenia symptoms in our 26-week trial. While unsatisfactory compliance questions the feasibility of patient-controlled neurostimulation in schizophrenia, the overall pattern of symptom change might warrant further investigations in this population."],["dc.description.sponsorship","CerboMed GmbH, Erlangen, Germany"],["dc.identifier.doi","10.1007/s00406-015-0618-9"],["dc.identifier.isi","000361397100006"],["dc.identifier.pmid","26210303"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35876"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1433-8491"],["dc.relation.issn","0940-1334"],["dc.title","Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S4"],["dc.bibliographiccitation.journal","Schizophrenia Bulletin"],["dc.bibliographiccitation.lastpage","S12"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Wetzestein, Katharina"],["dc.contributor.author","Nowastowski, Verena"],["dc.contributor.author","Bernstein, Hans-Gert"],["dc.contributor.author","Steiner, Johann"],["dc.contributor.author","Schneider-Axmann, Thomas"],["dc.contributor.author","Kraus, Theo F. J."],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Bogerts, Bernhard"],["dc.contributor.author","Schmitz, Christoph"],["dc.contributor.author","Schmitt, Andrea"],["dc.date.accessioned","2018-11-07T10:11:48Z"],["dc.date.available","2018-11-07T10:11:48Z"],["dc.date.issued","2016"],["dc.description.abstract","The hippocampus is involved in cognition as well as emotion, with deficits in both domains consistently described in schizophrenia. Moreover, the whole volumes of both the anterior and posterior region have been reported to be decreased in schizophrenia patients. While fewer oligodendrocyte numbers in the left and right cornu ammonis CA4 subregion of the posterior part of the hippocampus have been reported, the aim of this stereological study was to investigate cell numbers in either the dentate gyrus (DG) or subregions of the anterior hippocampus. In this design-based stereological study of the anterior part of the hippocampus comparing 10 patients with schizophrenia to 10 age- and gender-matched healthy controls were examined. Patients showed a decreased number of oligodendrocytes in the left CA4, fewer neurons in the left DG and smaller volumes in both the left CA4 and DG, which correlated with oligodendrocyte and neuron numbers, respectively. When exploring the total hippocampus, keeping previously published own results from the posterior part of the same brains in mind, both decreased oligodendrocyte numbers in the left CA4 and reduced volume remained significant. The decreased oligodendrocyte number speaks for a deficit in myelination and connectivity in schizophrenia which may originate from disturbed maturational processes. The reduced neuron number of the DG in the anterior hippocampus may well point to a reduced capacity of this region to produce new neurons up to adulthood. Both mechanisms may be involved in cognitive dysfunction in schizophrenia patients."],["dc.identifier.doi","10.1093/schbul/sbv157"],["dc.identifier.isi","000386210400002"],["dc.identifier.pmid","27460617"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40116"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","1745-1701"],["dc.relation.issn","0586-7614"],["dc.title","Decreased Oligodendrocyte and Neuron Number in Anterior Hippocampal Areas and the Entire Hippocampus in Schizophrenia: A Stereological Postmortem Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","The International Journal of Neuropsychopharmacology"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Strube, Wolfgang"],["dc.contributor.author","Nitsche, Michael A."],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Bunse, Tilmann"],["dc.contributor.author","Rein, Bettina"],["dc.contributor.author","Herrmann, Maximiliane"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Nieratschker, Vanessa"],["dc.contributor.author","Witt, Stephanie H."],["dc.contributor.author","Rietschel, Marcella"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Hasan, Alkomiet"],["dc.date.accessioned","2018-11-07T10:01:13Z"],["dc.date.available","2018-11-07T10:01:13Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Brain-derived neurotrophic factor (BDNF) has been shown to be a moderator of neuroplasticity. A frequent BDNF-polymorphism (Val66Met) is associated with impairments of cortical plasticity. In patients with schizophrenia, reduced neuroplastic responses following non-invasive brain stimulation have been reported consistently. Various studies have indicated a relationship between the BDNF-Val66Met-polymorphism and motor-cortical plasticity in healthy individuals, but schizophrenia patients have yet to be investigated. The aim of this proof-of-concept study was, therefore, to test the impact of the BDNF-Val66Met-polymorphism on inhibitory and facilitatory cortical plasticity in schizophrenia patients. Methods: Cortical plasticity was investigated in 22 schizophrenia patients and 35 healthy controls using anodal and cathodal transcranial direct-current stimulation (tDCS) applied to the left primary motor cortex. Animal and human research indicates that excitability shifts following anodal and cathodal tDCS are related to molecular long-term potentiation and long-term depression. To test motor-cortical excitability before and after tDCS, well-established single-and paired-pulse transcranial magnetic stimulation protocols were applied. Results: Our analysis revealed increased glutamate-mediated intracortical facilitation in met-heterozygotes compared to val-homozygotes at baseline. Following cathodal tDCS, schizophrenia met-heterozygotes had reduced gamma-amino-butyric-acid-mediated short-interval intracortical inhibition, whereas healthy met-heterozygotes displayed the opposite effect. The BDNF-Val66Met-polymorphism did not influence single-pulse motor-evoked potential amplitudes after tDCS. Conclusions: These preliminary findings support the notion of an association of the BDNF-Val66Met-polymorphism with observable alterations in plasticity following cathodal tDCS in schizophrenia patients. This indicates a complex interaction between inhibitory intracortical interneuron-networks, cortical plasticity, and the BDNF-Val66Met-polymorphism. Further replication and validation need to be dedicated to this question to confirm this relationship."],["dc.description.sponsorship","AstraZeneca; I3G; AOK"],["dc.identifier.doi","10.1093/ijnp/pyu040"],["dc.identifier.isi","000352536800005"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11781"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37969"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","1469-5111"],["dc.relation.issn","1461-1457"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","BDNF-Val66Met-Polymorphism Impact on Cortical Plasticity in Schizophrenia Patients: A Proof-of-Concept Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","370"],["dc.bibliographiccitation.journal","Schizophrenia Research"],["dc.bibliographiccitation.lastpage","376"],["dc.bibliographiccitation.volume","208"],["dc.contributor.author","Wagner, Elias"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Kunze, Birgit"],["dc.contributor.author","Langguth, Berthold"],["dc.contributor.author","Landgrebe, Michael"],["dc.contributor.author","Eichhammer, Peter"],["dc.contributor.author","Frank, Elmar"],["dc.contributor.author","Cordes, Joachim"],["dc.contributor.author","Wölwer, Wolfgang"],["dc.contributor.author","Winterer, Georg"],["dc.contributor.author","Gaebel, Wolfgang"],["dc.contributor.author","Hajak, Göran"],["dc.contributor.author","Ohmann, Christian"],["dc.contributor.author","Verde, Pablo E."],["dc.contributor.author","Rietschel, Marcella"],["dc.contributor.author","Ahmed, Raees"],["dc.contributor.author","Honer, William G."],["dc.contributor.author","Siskind, Dan"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Strube, Wolfgang"],["dc.contributor.author","Schneider-Axmann, Thomas"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Hasan, Alkomiet"],["dc.date.accessioned","2020-12-10T15:21:10Z"],["dc.date.available","2020-12-10T15:21:10Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.schres.2019.01.021"],["dc.identifier.issn","0920-9964"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72938"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","451"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","467"],["dc.bibliographiccitation.volume","263"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Reich-Erkelenz, Daniela"],["dc.contributor.author","Oertel-Knoechel, Viola"],["dc.contributor.author","Keller, Katriona"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Scheewe, Thomas W."],["dc.contributor.author","Cahn, Wiepke"],["dc.contributor.author","Kahn, Rene S."],["dc.contributor.author","Falkai, Peter"],["dc.date.accessioned","2018-11-07T09:20:46Z"],["dc.date.available","2018-11-07T09:20:46Z"],["dc.date.issued","2013"],["dc.description.abstract","Affective and non-affective psychoses are severe and frequent psychiatric disorders. Amongst others, they not only have a profound impact on affected individuals through their symptomatology, but also regarding cognition, brain structure and function. Cognitive impairment influences patients' quality of life as well as their ability to work and being employed. While exercise therapy has been implemented in the treatment of psychiatric conditions since the days of Kraepelin and Bleuler, the underlying mechanisms have never been systematically studied. Since the early 1990s, studies emerged examining the effect of physical exercise in animal models, revealing stimulation of neurogenesis, synaptogenesis and neurotransmission. Based on that body of work, clinical studies have been carried out in both healthy humans and in patient populations. These studies differ with regard to homogenous study samples, sample size, type and duration of exercise, outcome variables and measurement techniques. Based on their review, we draw conclusions regarding recommendations for future research strategies showing that modern therapeutic approaches should include physical exercise as part of a multimodal intervention programme to improve psychopathology and cognitive symptoms in schizophrenia and affective disorders."],["dc.identifier.doi","10.1007/s00406-013-0423-2"],["dc.identifier.isi","000323513800002"],["dc.identifier.pmid","23873090"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28953"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1433-8491"],["dc.relation.issn","0940-1334"],["dc.title","The effects of physical exercise in schizophrenia and affective disorders"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.contributor.author","Maurus, Isabel"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Roeh, Astrid"],["dc.contributor.author","Keeser, Daniel"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Schneider-Axmann, Thomas"],["dc.contributor.author","Hellmich, Martin"],["dc.contributor.author","Schmied, Sabine"],["dc.contributor.author","Falkai, Peter"],["dc.date.accessioned","2021-08-12T07:46:10Z"],["dc.date.available","2021-08-12T07:46:10Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1007/s00406-021-01289-1"],["dc.identifier.pii","1289"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88632"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.relation.eissn","1433-8491"],["dc.relation.iserratumof","/handle/2/81411"],["dc.relation.issn","0940-1334"],["dc.title","Correction to: Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","erratum_ja"],["dspace.entity.type","Publication"]]